Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01810315
Other study ID # A12-124
Secondary ID
Status Completed
Phase Phase 1
First received March 11, 2013
Last updated April 9, 2015
Start date September 2013
Est. completion date October 2014

Study information

Verified date April 2015
Source CONRAD
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Purpose of the study is to assess tenofovir (TFV) PK and PD endpoints, cervicovaginal safety parameters, susceptibility to HIV-1 infection, and objective measures of vaginal applicator use in premenopausal and postmenopausal women.


Description:

Premenopausal women: Baseline blood and genital samples will be taken in the follicular and luteal phase (visits 2 and 3). The participant will be given TFV gel and instructed to insert two doses, separated by 2 hours, and return to the clinic 3 hours after the second insertion for blood and genital samples (visits 4/4a and 5/5a).

Postmenopausal women: Premenopausal women: Baseline blood and genital samples will be taken (visit 2). The participant will be given TFV gel and instructed to insert two doses, separated by 2 hours, and return to the clinic 3 hours after the second insertion for blood and genital samples (visit 3/3a). Estradiol cream will be distributed at visit 4. Post estradiol blood and genital samples will be taken at Visit 5. The participant will given TFV gel and instructed to insert 2 doses as before, while continuing to use the estradiol cream. Post TFV gel and estradiol cream blood and genital samples will be taken (visit 6/6a).


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 89 Years
Eligibility Inclusion Criteria: All volunteers

- In good healthsignificant systemic disease

- Not at risk of an STI, meaning: In a monogamous heterosexual or same sex relationship for at least the last four months with a partner who is not known to be HIV positive and has no known risks for STIs OR sexually abstinent

- Willing and able to comply with study procedures

- Normal Pap smear (by written report) in the past year.

Inclusion Criteria: Premenopausal volunteers

- 21-to-45 years of age

- Not at risk for pregnancy, meaning:

- Regular menstrual cycles (every 24 - 35 days)

- Luteal phase P level of greater than or equal to 3 ng/ml

Inclusion Criteria: Postmenopausal volunteers

- 46-89 years of age OR both ovaries removed at least 30 days prior to Visit 1

- No menstrual periods/vaginal bleeding in the past 12 months OR both ovaries removed at least 30 days prior to Visit 1

- FSH level of greater than or equal to 20 MIU/ml

Exclusion Criteria: All volunteers

- Clinically significant history of an abnormal Pap smear in the past year

- Surgery or biopsy of the vagina or cervix within 30 days

- Current STI or lower genital tract infection

- Current use of chronic immunosuppressants

- Current presence of vulvar, anal and/or vaginal genital warts

- Current tobacco use of any amount

- History of sensitivity/allergy to any component of the study product, topical anesthetic, or allergy to silver nitrate and/or Monsel's solution

- Known bleeding disorder that could lead to prolonged or continuous bleeding

- Grade 1 or higher laboratory abnormality, per the August 2009 update of the DAIDS Table for Grading the Severity of Adverse Events

- Systemic use in the last two weeks or anticipated use during the study of any of the following: corticosteroids, antibiotics, anticoagulants or other drugs known to prolong bleeding and/or clotting, antifungals, antivirals or antiretrovirals.

- Investigator discretion

- Current participation in any other drug or device study

Exclusion Criteria: Premenopausal women

- Use of DMPA in last six months

- Use of any other hormonal contraceptive method without 2 subsequent, normal menses since stopping hormonal contraceptives

- Current use of copper IUD

- Currently pregnant or pregnancy within the past 3 months

- Currently breastfeeding/having breastfed an infant in the last 2 months

Exclusion Criteria: Postmenopausal women

- Use of any hormonal medications in the past 30 days

- Contraindications to vaginal estrogen cream

Study Design

Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
TFV 1% gel

Estradiol vaginal cream


Locations

Country Name City State
United States Clinical Research Center, Eastern Virginia Medical School Norfolk Virginia

Sponsors (1)

Lead Sponsor Collaborator
CONRAD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentrations of tenofovir in plasma, vaginal aspirate, and genital tissue 3 hours after dosing No
Primary Concentrations of TFV-DP in genital tissue 3 hours after dosing No
See also
  Status Clinical Trial Phase
Completed NCT03411577 - Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program N/A
Active, not recruiting NCT03112369 - Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use N/A
Not yet recruiting NCT03642314 - HIV Self-testing in Implementation PrEP Study N/A
Completed NCT00984971 - Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Phase 1
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Active, not recruiting NCT03255915 - PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) Early Phase 1
Completed NCT05037513 - Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky N/A
Recruiting NCT05087680 - An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South N/A
Recruiting NCT05804461 - Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico N/A
Completed NCT03148171 - Project WERK (Wellness Encouragement Respect Kinship) N/A
Completed NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults Early Phase 1
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Active, not recruiting NCT03977181 - The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms N/A
Recruiting NCT05165745 - Stick2PrEP Cisgender Women and Trans Individuals N/A
Completed NCT03719053 - Single Dose Truvada Study Phase 1
Recruiting NCT03856580 - Long-acting Biomedical HIV Prevention in Transgender Women N/A
Completed NCT02750540 - Optimization of a Tenofovir Enema for HIV Prevention Phase 1
Completed NCT01386294 - Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection Phase 3
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1
Completed NCT01028157 - S.T.A.R.S.: Sistas Talking About Real Solutions Phase 1